{"id":12828,"date":"2025-09-24T11:16:42","date_gmt":"2025-09-24T09:16:42","guid":{"rendered":"https:\/\/mohnfoundation.no\/?page_id=12828"},"modified":"2025-09-24T13:17:27","modified_gmt":"2025-09-24T11:17:27","slug":"advanced-clinical-cancer-studies","status":"publish","type":"page","link":"https:\/\/mohnfoundation.no\/en\/https-mohnfoundation-no-en-thematic-initiatives-womens-health\/advanced-clinical-cancer-studies\/","title":{"rendered":"Advanced clinical cancer studies"},"content":{"rendered":"

[vc_row el_class=”article-white” css=”.vc_custom_1699529085046{margin-right: 0px !important;margin-left: 0px !important;}”][vc_column][vc_separator][vc_row_inner css=”.vc_custom_1650537879673{margin-bottom: -30px !important;}”][vc_column_inner]

Advanced clinical cancer studies<\/h1><\/div>[\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=”2\/3″][vc_column_text css=””]More than 340,000 Norwegians have or have had cancer, and the number is expected to rise in the coming years. The goal of this thematic initiative is to develop more targeted cancer treatments and offer new hope to patients with serious forms of cancer.
\nThe three clinical studies that have received funding are projects at Haukeland University Hospital:<\/p>\n

STARS \u2013 New combination treatment for aggressive brain tumors<\/strong>
\nThis project, led by Bente Skeie, investigates a new treatment strategy for glioblastoma (GBM). Even after surgery, radiation, and chemotherapy, most patients experience rapid relapse, and no effective treatment currently exists.
\nThe tumor protects itself from radiation by producing antioxidants that reduce the treatment\u2019s effectiveness. Researchers believe that sulfasalazine (SAS), a well-known drug, may inhibit this protection and make radiation more effective. A larger international study with 108 patients is now being planned, where the effect of this drug will be tested over three months.<\/p>\n

HUVAMER \u2013 Home-based treatment for blood cancer<\/strong>
\nThis project, led by Bj\u00f8rn Tore Gjertsen, aims to develop a new and more accessible treatment for acute myeloid leukemia (AML). AML occurs most frequently in older individuals, and survival rates are low \u2013 only one in four patients survives after three years.
\nAlthough treatments exist, they often lose effectiveness over time. The HUVAMER project, led by Bj\u00f8rn Tore Gjertsen, explores a new combination of medications with the goal of achieving safe, cost-effective, and home-based treatment.
\nResearchers will identify biological markers that indicate who benefits from the treatment, enabling more precise and effective therapy.<\/p>\n

NorCUP \u2013 The search for cancer\u2019s origin<\/strong>
\nThis project addresses cancer of unknown primary origin, also known as CUP. In CUP, the cancer has already spread, but it is not possible to identify where it first arose, making targeted treatment challenging. The condition is rare but serious \u2013 only one in five patients survives one year after diagnosis.
\nIn the NorCUP project, led by Stian Knappskog, researchers use advanced analyses to determine where the cancer originated. The goal is more precise and personalized treatment that can offer better prospects for patients.<\/p>\n

\"\"
Haukeland University Hospital<\/figcaption><\/figure>\n

[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/3″]

\n
\n
\n

Fact Box:<\/strong><\/p>\n